At the Extraordinary General Meeting (the "EGM") held on July 15, 2021 it was resolved in accordance with the proposal by the Board of Directors to authorize the Board of Directors to resolve on entry into a credit facility with the European Investment Bank (EIB), where the interest rate or the amount to be repaid is raised should the result of the Company or dividend paid to shareholders of the Company, if any, increase.
The complete proposal by the Board of Directors is included in the notice to convene the EGM, which is available on IRRAS AB’s website www.irras.com.
IRRAS is a global medical care company focused on innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
Director, Investor Relations
Mobile: +46 721 44 7244
The information was released for public disclosure, through the agency of the contact persons above, on July 15, 2021 at 14:00 (CET).